Burning Rock Biotech (BNR) Cash & Current Investments (2021 - 2023)

Burning Rock Biotech has reported Cash & Current Investments over the past 3 years, most recently at $85.4 million for Q4 2023.

  • Quarterly results put Cash & Current Investments at $85.4 million for Q4 2023, down 34.32% from a year ago — trailing twelve months through Dec 2023 was $85.4 million (down 34.32% YoY), and the annual figure for FY2023 was $86.7 million, down 37.12%.
  • Cash & Current Investments for Q4 2023 was $85.4 million at Burning Rock Biotech, down from $130.1 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for BNR hit a ceiling of $225.1 million in Q4 2021 and a floor of $85.4 million in Q4 2023.
  • Median Cash & Current Investments over the past 3 years was $130.1 million (2022), compared with a mean of $146.9 million.
  • Biggest five-year swings in Cash & Current Investments: crashed 42.2% in 2022 and later crashed 34.32% in 2023.
  • Burning Rock Biotech's Cash & Current Investments stood at $225.1 million in 2021, then crashed by 42.2% to $130.1 million in 2022, then crashed by 34.32% to $85.4 million in 2023.
  • The last three reported values for Cash & Current Investments were $85.4 million (Q4 2023), $130.1 million (Q4 2022), and $225.1 million (Q4 2021) per Business Quant data.